Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants

Molecular Pharmacology

Volumn 54, Issue 1, 1998, Pages 213-219

  Perego, Paola ^a,d   Zunino, Franco ^a   Carenini, Nives ^a   Giuliani, Fernando ^b   Spinelli, Silvano ^b   Howell, Stephen B ^c  

^a Boehringer Ingelheim Italia SpA   (Italy)

^b Boehringer Mannheim Italia   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BBR 3464; CISPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; SATRAPLATIN; TETRAPLATIN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CYTOTOXICITY; DNA REPAIR; DRUG SENSITIVITY; FUNGUS MUTANT; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; SCHIZOSACCHAROMYCES POMBE;

SCHIZOSACCHAROMYCES POMBE;

EID: 0031845331     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.1.213     Document Type: Article

References (28)

1. Al-Khodairy F, Fotou E, Sheldrick KS, Griffiths DFJ, Lehmann AR, and Carr AM (1994) Identification and characterization of new elements involved in checkpoint and feedback controls in fission yeast. Mol Biol Cell 5:147-160.
2. Bentley NJ, Holtzman DA, Flaggs G, Keegan KS, DeMaggio A, Ford JC, Hoekstra M, and Carr AM. (1996) The Schizosacchoromyces pombe rad3 checkpoint gene. EMBO J 23:6641-6651.
3. Bootsma D (1993) The genetic defect in DNA repair deficiency syndromes. EACR -Muhlbock Memorial Lecture, 1993. Eur J Cancer 29A:1482-1488.
4. Carr AM, Smidt H, Kirchhohh S, Muriel WJ, Sheldrick KS, Griffiths DJ, Basmacioglu CN, Subramani S, Clegg M, Nasim A, and Lehmann AR (1994) The rad16 gene of Schizosaccharomyces pombe: a homolog of the RAD1 gene of Saccharomyces pombe. Mol Cell Biol 14:2029-2040.
5. Dabholkar M, Vionnet J, Bostick Bruton F, Yu JJ, and Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703-708.
6. Dancey J, and Le Chevalier T (1997) Non-small cell lung cancer: an overview of current management. Eur J Cancer 33:S2-S7.
7. Eastman A (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34:155-166.
8. Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2:275-280.
9. Farrel N, Qu Y, and Hacker MP (1990) Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem 33:2179-2184.
10. Farrell N (1993) Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin. Cancer Invest 11:578-589.
11. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, and Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886.
12. Giuliani FC, Beggiolin, Pezzoni G, Formento ML, Di Blasi P, Farrell N, Kelland L, Caserini C, Perego P, Supino R, and Zunino F (1997) Pattern of cellular sensitivity to BBR 3464, a novel trinuclear platinum complex, in human tumor cell lines: lack of cross-resistance with cisplatin. Proc Am Assoc Cancer Res Annu Meet 38:310.
13. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, and Friend SH (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science (Washington DC) 278:1064-1068.
14. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, and Harrap KR (1989) Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59:527-534.
15. Huang JC, Zamble DB, Reardon JT, Lippard SJ, and Sancar A (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 91:10394-10398.
16. Kelland LR, Barnard CFJ, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, and Harrap KR (1994) A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res 54:5618-5622.
17. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, and Harrap KR (1992) Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 52:822-828.
18. Lehmann AR, Walicka M, Griffiths DJF, Murray JM, Watts FZ, McReady S, and Carr AM (1995) The rad18 gene of schizosaccharomyces pombe defines a new subgroup of the SMC superfamily involved in DNA repair. Mol Cell Biol 15:7067.
19. Loh SY, Mistry P, Kelland LR, Abel G, and Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66:1109-1115.
20. Mellish KJ, Kelland LR, and Harrap KR (1993) In vitro platinum drug chemosensitivity of intrinsic and acquired cisplatin-resistant human cervical carcinoma cell lines. Br J Cancer 68:240-250.
21. Ormerod MG, O'Neill C, Robertson D, Kelland L, and Harrap K (1996) Cisdiammine-dichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37:463-471.
22. Ozols RF, and Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 16:58-65.
23. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562.
24. Pratesi G, Giuliani FC, Polizzi D, Righetti S, Manzotti C, Pezzoni G, Farrell N, and Zunino F (1997) Complete lack of cross-resistance of cisplatin-resistant tumors to a novel charged trinuclear platinum complex: p53-independent antitumor efficacy. Proc Am Assoc Cancer Res Annu Meet 38:310.
25. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, and Fojo T (1997) Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of aht National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52:1855-1865.
26. Rowley R, Subramani S, and Young PG (1992) Checkpoint controls in Schizosaccharomyces pombe: rad1. EMBO J 11:1335-1342.
27. Subramani S (1991) Radiation resistance in Schizosaccharomyces pombe. Mol Microbiol 5:2311-2314.
28. Szymkowski DE, Yarema K, Essigmann JM, and Lippard SJ (1992) An intrastrand d(GpG) platinum cross-link in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 89:10772-10776.